Teva Pharmaceuticals Hopes $40 Billion Mylan Deal Will Fuel Stock Rebound

April 21, 2015 5:09 PM

68 0

In the red hot market for pharmaceutical deal-making it’s either eat or be eaten. That’s the case with Teva Pharmaceutical’s $82 a share cash and stock bid for generic competitor Mylan Mylan, a direct challenge to Mylan’s near $30 billion takeover bid for Perrigo Perrigo, unveiled on April 8.

The question now is whether Mylan’s board of directors and its stockholders will cast their lot with Teva Pharmaceuticals, a company that’s seen its stock dramatically underperform the S&P 500 Index over the past five years, or whether they will continue to support a management team led by CEO Heath...

Read more

To category page